# Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

> **NCT00345579** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 4432 (actual)

## Conditions studied

- Haemophilus Influenzae Type b
- Neisseria Meningitidis

## Interventions

- **BIOLOGICAL:** GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014
- **BIOLOGICAL:** ActHIB
- **BIOLOGICAL:** Pediarix/Infanrix Penta

## Key facts

- **NCT ID:** NCT00345579
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-10
- **Final completion:** 2008-03
- **Target enrollment:** 4432 (ACTUAL)
- **Last updated:** 2016-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00345579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00345579, "Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00345579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*